IBA's myQA MatriXX AiR: Positioning for Recurring Revenue in Next-Gen Radiotherapy Adoption

IBA is making a calculated bet on the infrastructure layer for the next paradigm in cancer treatment. The launch of the myQA MatriXX AiR is not just a product update; it's a strategic move to become the essential quality assurance provider for emerging particle therapy techniques. This system is engineered for the future, featuring a dense array of 1,521 high-resolution air-vented ionization chambers and a wireless design that enables fast, reliable verification for complex treatments like FLASH and ARC radiotherapy. Its 20ms readout speed is critical for keeping pace with the ultra-high-dose-rate delivery these next-gen modalities demand.

This foundational play is backed by a strong financial position. The company recently reported a record-high revenue and return to profitability in 2024, with a significant gross margin improvement to 33.3%. This profitability provides the capital to fund strategic R&D and market expansion. More importantly, it is supported by a stable €1.5 billion equipment and services backlog, which offers a predictable revenue stream and the financial capacity to execute long-term bets like this one.

The thesis here is clear: IBA is leveraging its market leadership to cement its role beyond just selling accelerators. By providing the indispensable QA infrastructure for the next generation of treatments, it creates a recurring revenue stream that complements its core equipment sales. This move positions the company to capture value at every stage of a center's adoption curve, from initial equipment purchase to ongoing verification needs. In the exponential growth phase of particle therapy, being the trusted partner for treatment confidence is a powerful competitive moat.

The Financial Engine: Backlog, Margins, and the Recurring Revenue Model

The strategic bet on QA infrastructure is being fueled by a powerful financial engine. IBA's 2024 results show a company successfully converting its massive backlog into real profit. The company reported a REBIT of €17.3 million, a staggering 170% increase from the prior year. This surge was driven almost entirely by the well-executed backlog conversion, particularly in its Other Accelerators segment. This operational leverage is further confirmed by a gross margin improvement to 33.3% from 28.8%, indicating the company is not just selling more but selling more efficiently.

This profitability provides the dry powder for future bets. At year-end, IBA held a €33.5 million net cash position, backed by a strong €60 million undrawn credit line. While the cash balance has started to decrease in the first quarter to €9 million as the company funds ongoing operations and investments, the underlying financial strength remains robust. This capital is critical for funding the R&D needed to develop next-generation products like the myQA MatriXX AiR.

The real strategic insight lies in the model this creates. The €1.5 billion equipment and services backlog provides a stable, predictable revenue foundation. This allows IBA to fund long-term innovation while maintaining financial discipline. The company's updated outlook targets a 10% REBIT margin by 2028, with 2025 guidance of at least €25 million, supported by growing recurring services revenue. The launch of the myQA system is a direct play on this recurring revenue stream. It moves IBA beyond one-time equipment sales into a model where it provides essential, ongoing verification services for each treatment delivered. This creates a more resilient and valuable business, one that captures value at every stage of a center's adoption curve for next-gen radiotherapy.

Adoption Curve and Competitive Landscape: Catalysts and Risks

The payoff for IBA's infrastructure bet hinges on the adoption rate of its core market. Proton and carbon-ion therapy are still in the early, steep part of their S-curve. The technology is proven, but the number of centers worldwide remains small. This creates a long runway for growth, but also means the company is investing in a future that is not yet fully realized. The exponential adoption of these advanced treatments is the fundamental driver that will eventually fuel demand for specialized QA systems like the myQA MatriXX AiR.

The next major catalyst is just days away. IBA is scheduled to release its full-year 2025 results on March 27th. This report will be a critical checkpoint. Investors will scrutinize whether the company is maintaining its momentum in converting the massive €1.5 billion backlog into profit, as it did so effectively in 2024. The margin trends and any updates on the recurring services revenue model will provide a clear signal on the health of the financial engine powering this strategic bet.

Yet, a key risk is slower-than-expected adoption of the very next-gen techniques the myQA system is built for. The system is engineered for emerging techniques such as FLASH and ARC radiotherapy. If the clinical adoption of FLASH, in particular, stalls or is delayed due to regulatory hurdles or unmet efficacy data, the near-term need for this specialized wireless QA hardware could be pushed out. This would compress the timeline for IBA to recoup its R&D investment and realize the full value of its infrastructure play.

On the competitive front, IBA's position is strong but not invulnerable. Its established market leadership in particle accelerators and its certified B Corp status are significant moats. These factors build trust and credibility, especially in a regulated healthcare environment where clinical confidence is paramount. However, the QA space is not immune to competition. As the market for particle therapy grows, other players may develop alternative verification solutions. IBA's first-mover advantage with a wireless, high-resolution array is a clear edge, but it must continue to innovate to maintain its lead as the standard-bearer for treatment confidence.

The bottom line is a high-stakes race between adoption and execution. The company is betting that the exponential growth curve of particle therapy will soon reach a point where specialized QA becomes a non-negotiable requirement. The upcoming results will show if it is on track to profit from that future, or if the adoption curve is moving slower than anticipated.